Cantargia publishes interim report for first quarter 2020
Cantargia AB’s (”Cantargia”) interim report for first quarter 2020 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.Significant events in the first quarter · Cantargia advanced its development of CAN04 by successfully scaling up production. · Cantargia completed a directed share issue which raised SEK 410 million before transaction costs. · Cantargia acquired a patent portfolio from Cellerant Therapeutics Inc. that includes a US patent on IL1RAP as target for antibody therapy in leukemia. Significant events after the end of the period